RAM
JSPR icon

Readystate Asset Management’s Jasper Therapeutics JSPR Stock Holding History

Readystate Asset Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,499
Closed -$24.1K – 983
2026
Q1 		$24.1K Sell
27,499
-70,940
-72% -$98.5K ﹤0.01% 781
2025
Q4 		$180K Hold
98,439
– – 0.01% 330
2025
Q3 		$234K Buy
+98,439
New +$299K 0.01% 286

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Readystate Asset Management's JSPR Position: Q2 2026 in Review

Readystate Asset Management sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 27,499 shares — an estimated $24.1K sold.

Readystate Asset Management first reported a position in JSPR in Q3 2025 and held it in 3 quarters. The position peaked at $234K in Q3 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Readystate Asset Management reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Readystate Asset Management sold 27,499 Jasper Therapeutics shares in Q2 2026, an estimated $24.1K.
  • Readystate Asset Management first reported a position in Jasper Therapeutics in Q3 2025 and held it in 3 quarters.
  • Readystate Asset Management's Jasper Therapeutics position peaked at $234K in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Readystate Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.